ArticleScientific reports2022

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination.

David J Dowling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.